slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
219,451-219,480 of 319,975
01
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
04
The slide uses a column-based layout with icons and supporting text to present company strengths.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent clinical trial progress.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to diagnosed to treated.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a process-flow diagram to show how different mechanisms of action (NA, RNAi, PD-L1 Inhibitor, Interferon, Vaccines) contribute to the three pillars of the therapeutic approach.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
The slide uses a bulleted list to summarize the therapeutic profile and a diagram to illustrate the mechanism of action targeting HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · ProductLoop · Cost Of Inaction1 hit
11
The slide outlines trial design cohorts (E, F, G, I, J, K) and summarizes findings from parts 1 & 2.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The table displays mean (SE) log10 IU/mL values for various cohorts (E, F, I, J, K, G) from baseline through follow-up week 48.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual subject responses.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
The slide displays 8 individual patient charts tracking biomarker levels over time, with specific annotations for NA retreatment.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
The slide uses a bulleted list format to present key safety findings.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
17
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
18
The slide uses a timeline-based process diagram to illustrate the randomization and treatment arms of the clinical trial.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
19
The slide outlines two distinct treatment arms involving Imdusiran, VTP-300, and Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
20
The slide details a specific licensing deal with Qilu Pharmaceutical.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
21
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
22
The slide uses a three-column layout to explain the scientific basis and therapeutic advantages of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
23
The slide shows two distinct experiments: an in vitro T-cell activation assay and an in vivo tumor reduction study.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
24
The slide outlines a sequential dose-escalation study design.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
25
The slide uses checkmarks to indicate completed milestones.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · Financials1 hit
26
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
01
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a background image of a sea with a network-like overlay, reinforcing the 'connected' or 'scientific' theme.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
04
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit